New hope for ankylosing spondylitis: Real-World study tests secukinumab in Biologic-Naive patients
NCT ID NCT06905288
First seen Feb 26, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study looks at how well secukinumab works for people with active ankylosing spondylitis who have never taken certain biologic drugs before. Researchers will track changes in disease activity and inflammation over time. The goal is to see if this treatment helps control symptoms in a real-world setting in Korea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGJinju, Gyeongsangnam-do, 52727, South Korea
-
Novartis Investigative Site
RECRUITINGBusan, 49201, South Korea
Conditions
Explore the condition pages connected to this study.